Nedbank CIB Advises Ethos on Vertice MedTech Exit to Amethis-Led Consortium

The African healthcare sector is attracting unprecedented interest from investors, with the Corporate Finance team at Nedbank Corporate and Investment Banking (CIB) playing a crucial role in this development.

Recently, the investment bank provided advisory services to Ethos during its strategic sale of a stake in Vertice MedTech, which drew interest from global buyers and underscores the increasing appeal of healthcare assets in emerging markets.

This transaction is part of Ethos Fund VI’s ongoing realization strategy, marking a significant milestone for Ethos and demonstrating Nedbank CIB’s advisory proficiency.

Vertice MedTech is recognized as a leading independent distributor of specialized medical devices and mobile healthcare solutions.

The company is essential to healthcare delivery in South Africa and across other African regions, facilitating over 7,000 surgeries monthly while supporting national health initiatives through mobile medical units.

Its services include advanced medical devices, software services, and health IT consulting—critical elements for improving healthcare access and outcomes in a region witnessing a significant rise in demand for modern medical solutions.

Moreover, the business is expanding its technological presence in Europe, reflecting the global trends of contemporary healthcare companies.

As the corporate advisor to both Ethos and Vertice MedTech, Nedbank CIB effectively managed a competitive process that attracted substantial interest from international purchasers.

This success emphasizes the bank’s expertise in executing complex private equity exits and cross-border transactions, especially in sectors requiring extensive technical knowledge and strategic insight.

“Healthcare remains a rapidly evolving and valuable investment domain,” says Avinash Kalkapersad, investment banking originator at Nedbank CIB.

“Our involvement in this transaction highlights our ability to deliver strategic outcomes for clients in sectors that truly matter.”

Michael Jensen, a partner at Ethos, remarks: “After successfully developing Vertice MedTech since its acquisition in 2018, we recognized it was the right time to exit in line with our broader asset realization strategy.

“Nedbank CIB’s expert guidance ensured a successful deal.”

This transaction comes at a time when healthcare investments in Africa are rising significantly, driven by demographic shifts, increased demand for specialized services, and the need for technology-driven solutions.

For investors, this sector presents a compelling mix of financial returns and social impact, making it one of the most attractive areas for capital investment in emerging markets.

By facilitating this transaction, Nedbank CIB has demonstrated its capability to secure global buyers for strategic African assets—a skill that is becoming increasingly essential as cross-border deals become more competitive.

The bank is positioned to play a significant role in the flourishing healthcare sector, fueled by aging populations, technological advancements, rising rates of chronic diseases, and the expansion of the global middle class.

For Nedbank CIB, this transaction symbolizes more than just a deal. It embodies the firm’s ability to integrate sector expertise with strategic insight, delivering solutions that bring value to clients and communities alike.

As healthcare investments accelerate across Africa, Nedbank CIB remains at the forefront, influencing the future of advisory excellence in the sectors that hold the most significance.

Healthcare is more than merely a financial opportunity; it profoundly impacts lives. Transactions like this allow companies like Vertice MedTech to continue providing vital services, promoting innovation, and improving health outcomes in Africa.

For investors and stakeholders, these deals represent the convergence of financial performance and social impact—a sphere in which Nedbank CIB is committed to leading.

Brought to you by Nedbank CIB.

Moneyweb does not endorse any product or service being advertised in sponsored articles on our platform.